Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 114 clinical trials
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (SABLe)

An open-label randomized (1:1) phase 2 study between a standard arm of VRD light versus an experimental arm of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly

lenalidomide
antibiotics
platelet count
neutrophil count
bone marrow procedure
  • 0 views
  • 10 May, 2022
  • 1 location
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

own to treat some blood cell cancers. Objectives To test the safety and efficacy of the drug combination of bortezomib and clofarabine.

advanced cancer
bisphosphonate
clofarabine
cancer
solid neoplasm
  • 25 views
  • 18 May, 2022
  • 1 location
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA))

This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.

plasmacytoma
lenalidomide
electrophoresis
revlimid
platelet count
  • 71 views
  • 09 Feb, 2022
  • 1 location
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that of VRD regimen.

plasmacytoma
lenalidomide
bortezomib
dexamethasone
platelet count
  • 10 views
  • 12 Feb, 2022
  • 1 location
Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease (EMN19)

This trial will try to establish the feasibility and efficacy of the combination of DaraVCD in Multiple Myeloma (MM) patients presenting with extramedullary disease (EMD). The study will be conducted as a Phase II trial. Forty patients will be included in the study cohort. All patients will be followed closely …

plasmacytoma
vasectomy
serum immunoglobulin a
daratumumab
immunoglobulins
  • 3 views
  • 18 Feb, 2022
  • 1 location
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide Bortezomib and Dexamethasone (CyBorD) for NDMM NTE

This is a phase 2A multi-centre, open label, pilot study of pembrolizumab added to the standard first-line therapy of cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed

bortezomib
dexamethasone
  • 0 views
  • 31 Jul, 2021
  • 4 locations
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

This phase II trial studies how well daratumumab, bortezomib, and dexamethasone followed by daratumumab, ixazomib, and dexamethasone in treating patients with multiple myeloma that has come back

bone lesions
daratumumab
induction therapy
progressive disease
growth factor
  • 3 views
  • 15 May, 2022
  • 1 location
Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

and bortezomib in adults with relapsed/refractory multiple myeloma (MM).

bortezomib
cancer
dexamethasone
measurable disease
refractory multiple myeloma
  • 0 views
  • 03 May, 2022
  • 6 locations
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

The phase 2 study evaluated the efficacy and safety of bortezomib in combination with lenalidomide as maintenance therapy in high risk newly diagnosed multiple myeloma patients who receive

plasmacytoma
lenalidomide
monoclonal antibodies
remission
neutrophil count
  • 0 views
  • 26 Jan, 2021
  • 1 location
Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in

bortezomib
cancer
chemotherapy regimen
multiple myeloma
peripheral neuropathy
  • 2 views
  • 21 Apr, 2022
  • 1 location